期刊
CARDIOVASCULAR RESEARCH
卷 79, 期 4, 页码 611-620出版社
OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvn154
关键词
drug delivery system; erythropoietin; Akt; VEGF; angiogenesis; myocardial infarction
资金
- Ministry of Education, Science and Culture of Japan [18590791]
- Grants-in-Aid for Scientific Research [18590791] Funding Source: KAKEN
Aims We investigated the effect of an erythropoietin (EPO)-gelatin hydrogel drug delivery system (DIDS) applied to the heart on myocardial infarct (MI) size, left ventricular (W) remodelling and function. Methods and results Experiments were performed in a rabbit model of MI. The infarct size was reduced, and LV remodelling and function were improved 14 days and 2 months after MI but not at 2 days after MI in the EPO-DDS group. The number of cluster of differentiation 31 (CD31)-positive microvessels and the expression of erythropoietin receptor (EPO-R), phosphorylated-Akt (p-Akt), phosphorylated glycogen synthase kinase 3 beta (p-GSK-3 beta), phosphorylated extracellular signal-regulated protein kinase (p-ERK), phosphorylated signal transducer and activator of transcription 3 (p-Stat3), vascular endothelial growth factor (VEGF), and matrix metalloproteinase-1 (MMP-1) were significantly increased in the myocardium of the EPO-DDS group. Conclusion Post-MI treatment with an EPO-DDS improves LV remodelling and function by activating pro-survival signalling, antifibrosis, and angiogenesis without causing any side effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据